Stable_JJ
expression_NN
of_IN
transdominant_JJ
Rev_NN
protein_NN
in_IN
human_JJ
T_NN
cells_NNS
inhibits_VBZ
human_JJ
immunodeficiency_NN
virus_NN
replication_NN
._.

The_DT
human_JJ
immunodeficiency_NN
virus_NN
-LRB-_-LRB-
HIV_NN
-RRB-_-RRB-
Rev_NN
protein_NN
is_VBZ
essential_JJ
for_IN
viral_JJ
structural_JJ
protein_NN
expression_NN
-LRB-_-LRB-
Gag_NN
,_,
Pol_NN
,_,
and_CC
Env_NN
-RRB-_-RRB-
and_CC
,_,
hence_RB
,_,
for_IN
viral_JJ
replication_NN
._.

In_IN
transient_JJ
transfection_NN
assays_NNS
,_,
mutant_JJ
forms_NNS
of_IN
Rev_NN
have_VBP
been_VBN
identified_VBN
that_IN
inhibit_VBP
wild-type_JJ
Rev_NN
activity_NN
and_CC
therefore_RB
suppress_VBP
viral_JJ
replication_NN
._.

To_TO
determine_VB
whether_IN
such_JJ
transdominant_JJ
Rev_NN
proteins_NNS
could_MD
provide_VB
long-term_JJ
protection_NN
against_IN
HIV_NN
infection_NN
without_IN
affecting_VBG
T_NN
cell_NN
function_NN
,_,
T_NN
leukemia_NN
cell_NN
lines_NNS
were_VBD
stably_RB
transduced_VBN
with_IN
a_DT
retroviral_JJ
vector_NN
encoding_VBG
a_DT
transdominant_JJ
mutant_NN
of_IN
the_DT
Rev_NN
protein_NN
,_,
M10_NN
._.

While_IN
all_PDT
the_DT
M10-expressing_JJ
cell_NN
lines_NNS
remained_VBD
infectable_JJ
by_IN
HIV-1_NN
,_,
these_DT
same_JJ
cells_NNS
failed_VBD
to_TO
support_VB
a_DT
productive_JJ
replication_NN
cycle_NN
when_WRB
infected_VBN
with_IN
a_DT
cloned_VBN
isolate_NN
of_IN
HIV-1_NN
._.

In_IN
addition_NN
,_,
two_CD
out_IN
of_IN
three_CD
M10-expressing_JJ
CEM_NN
clones_NNS
were_VBD
also_RB
resistant_JJ
to_TO
highly_RB
productive_JJ
infection_NN
by_IN
a_DT
heterogeneous_JJ
HIV-1_NN
pool_NN
._.

Expression_NN
of_IN
M10_NN
did_VBD
not_RB
affect_VB
induction_NN
of_IN
HIV_NN
transcription_NN
mediated_VBN
by_IN
the_DT
kappa_NN
B_NN
regulatory_JJ
element_NN
or_CC
Tat_NN
._.

Importantly_RB
,_,
constitutive_JJ
expression_NN
of_IN
Rev_NN
M10_NN
did_VBD
not_RB
alter_VB
the_DT
secretion_NN
of_IN
interleukin_NN
2_CD
in_IN
response_NN
to_TO
mitogen_NN
stimulation_NN
of_IN
EL-4_NN
and_CC
Jurkat_NN
cells_NNS
._.

The_DT
inhibition_NN
of_IN
HIV_NN
infection_NN
in_IN
cells_NNS
stably_RB
expressing_VBG
a_DT
transdominant_JJ
Rev_NN
protein_NN
,_,
in_IN
the_DT
absence_NN
of_IN
any_DT
deleterious_JJ
effect_NN
on_IN
T_NN
cell_NN
function_NN
,_,
suggests_VBZ
that_IN
such_PDT
a_DT
strategy_NN
could_MD
provide_VB
a_DT
therapeutic_JJ
effect_NN
in_IN
the_DT
T_NN
lymphocytes_NNS
of_IN
acquired_VBN
immunodeficiency_NN
syndrome_NN
patients_NNS
._.

